Dara Azar
Stock Analyst at Stifel Nicolaus
(2.18)
# 3,123
Out of 4,516 analysts
12
Total ratings
37.5%
Success rate
4.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dara Azar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ELVN Enliven Therapeutics | Maintained: Buy | $60 → $80 | $53.16 | +50.49% | 2 | Jul 1, 2026 | |
| INBX Inhibrx Biosciences | Maintained: Buy | $325 | $91.22 | +256.28% | 5 | Jun 2, 2026 | |
| SMMT Summit Therapeutics | Maintained: Buy | $45 | $15.07 | +198.61% | 5 | Jun 1, 2026 |
Enliven Therapeutics
Jul 1, 2026
Maintained: Buy
Price Target: $60 → $80
Current: $53.16
Upside: +50.49%
Inhibrx Biosciences
Jun 2, 2026
Maintained: Buy
Price Target: $325
Current: $91.22
Upside: +256.28%
Summit Therapeutics
Jun 1, 2026
Maintained: Buy
Price Target: $45
Current: $15.07
Upside: +198.61%